查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806344

良性前列腺增生治療市場（按治療類型、產品類型、最終用戶和分銷管道）—2025-2030 年全球預測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

良性攝護腺增生 (BPH) 治療市場預計在 2024 年達到 87.1 億美元，2025 年達到 92 億美元，2030 年達到 123 億美元，複合年成長率為 5.91%。

主要市場統計數據
基準年2024年 87.1億美元
預計2025年 92億美元
預測年份 2030 123億美元
複合年成長率（%） 5.91%

探索定義下一代 BPH 治療模式的新興臨床發展和市場驅動力

良性前列腺增生 (BPH) 因其在老年男性群體中的高發性及其對生活品質的嚴重影響而成為臨床上一個重要的研究領域。隨著患者族群老化趨勢的加速，全球醫療保健系統面臨越來越大的壓力，需要提供安全、有效且經濟實惠的治療方案。近年來，臨床創新、患者偏好以及不斷變化的報銷途徑的相互作用，在一定程度上重新定義了與 BPH 相關的中度至重度下泌尿道症狀的治療目標。

確定影響良性前列腺增生治療的治療方法和患者預後的基本技術和監管變化

由於技術突破和法律規範的不斷變化，良性前列腺增生的治療格局正在發生深刻的變化。該領域過去嚴重依賴藥物治療和經尿道電切手術，如今正見證尖端能量治療方法、影像導引介入和標靶栓塞治療的興起。這些創新旨在最大限度地降低手術併發症發生率，同時保留泌尿和性功能，而這正是當今患者群體的首要任務。

美國關稅調整前列腺增生治療供應鏈及創新路徑的收斂效應分析

美國宣布的2025年關稅調整正在對全球供應鏈產生連鎖反應，影響良性前列腺增生（BPH）治療關鍵零件的成本結構和可及性。從導管和切除鏡到泌尿系統雷射和植入，許多醫療設備都源自海外或包含海外製造的零件。隨著進口關稅的提高，經銷商和醫療保健提供者面臨採購成本增加的問題，進而影響價格談判和報銷談判。

揭示細分治療型產品最終用戶和分銷管道的洞察，塑造 BPH 管理方法

對市場區隔的細緻理解，揭示了策略投資和產品開發的關鍵曲折點。就治療類型而言，藥物治療仍然至關重要，5α還原酶抑制劑和α阻斷劑仍然是第一線藥物干預措施。然而，包括前列腺動脈栓塞和水蒸氣療法在內的微創治療領域因其較短的恢復時間和良好的安全性，正迅速普及。同時，外科手術治療也日趨多樣化，已超越傳統的經尿道前列腺切除術，包括雷射手術、前列腺尿道抬高術以及優先考慮最小組織損傷的經尿道技術。

評估美洲、歐洲、中東、非洲和亞太地區的地理市場動態，為制定有針對性的 BPH 治療策略提供參考

區域動態在塑造良性前列腺增生 (BPH) 治療生態系統中發揮關鍵作用，每個地區都有其獨特的監管、臨床和經濟考量。在美洲，完善的報銷框架和早期技術應用，加上廣泛的臨床試驗網路和成熟的支付方-醫療機構合作關係，正在促進基於設備的治療與先進醫療療法的快速整合。

創新策略夥伴關係領先生物製藥設備技術公司在前列腺增生治療領域的合作競爭態勢

BPH 領域的競爭格局由成熟製藥公司和創新設備製造商的混合體決定，領先的製藥公司利用數十年的 5α-還原酶抑製劑和 α-受體阻滯劑組合經驗，而鄰近的生物製藥公司則探索解決症狀緩解和組織重塑的新型聯合治療。

制定可行的策略建議，以提高前列腺增生治療的市場滲透率和患者對臨床療效的接受度

具有前瞻性的行業領導者應優先考慮多管齊下的策略，以在不斷發展的良性前列腺增生 (BPH) 市場中保持競爭優勢。首先，投資下一代微創技術，尤其是門診或診室應用，可以滿足患者對縮短復原時間和維持生活品質的需求。與關鍵意見領袖和高容量中心建立合作試驗計畫，可以加速該技術的採用曲線，並產生令人信服的真實世界證據，以支持報銷談判。

嚴格的數據收集、分析和檢驗通訊協定的詳細資訊，確保在 BPH 市場評估中獲得可靠的結果

本研究採用了嚴謹的方法，將全面的二手資料研究與有針對性的一手資料訪談和資料三角檢定結合。我們首先系統性地分析了同行評審日誌、監管資料庫、專利申請和產業白皮書，以治療方法和設備創新及政策發展的堅實基準。我們整理了過往的監管核准和指南修訂情況，以確定關鍵市場變化的時機和範圍。

綜合關鍵發現與策略意義，確定良性攝護腺增生治療領域的未來方向與機會

主要發現總結了市場正處於一個重要的轉折點。微創治療方法的進步、監管調整以及關稅下供應鏈的強化正在重塑治療流程和競爭動態。細分分析凸顯了非手術干預和專科產品類型日益成長的重要性，而區域洞察則強調了在美洲、歐洲、中東和非洲以及亞太地區製定打入市場策略的必要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 患者對微創治療的需求推動了經尿道水蒸氣消融術的普及
  • 遠端醫療平台的成長實現了遠距症狀監測和個人化 BPH 藥物管理
  • 旨在改善副作用的選擇性 5α-還原酶抑制劑的開發激增
  • 門診前列腺尿道拉提手術的擴展降低了手術成本並縮短了恢復時間。
  • 整合人工智慧診斷工具，用於早期發現和 BPH 進展風險分層
  • 越來越多的真實世界證據研究影響了 BPH 治療和介入的價值型報銷
  • BETA-3促效劑和 α阻斷劑聯合治療的出現，增強了泌尿道症狀的緩解
  • 基於藥物基因組學分析的個人化給藥通訊協定，以最佳化 BPH 患者的治療結果

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：良性攝護腺增生治療市場（依治療類型）

  • 製藥
    • 5α-還原酶抑制劑
    • α受體阻斷劑
  • 微創治療
    • 攝護腺動脈栓塞術
    • 水蒸氣療法
  • 手術治療
    • 雷射手術
    • 前列腺尿道抬高術
    • 經尿道前列腺切開術
    • 經尿道前列腺切除術

9. 前列腺增生治療市場（依產品類型）

  • 導管
  • 電極
  • 植入
  • 攝護腺支架
  • 電切鏡
  • 泌尿系統雷射

第 10 章。良性攝護腺增生治療市場（依最終使用者）

  • 門診手術中心
  • 診所
  • 居家護理
  • 醫院

第 11 章。良性攝護腺增生治療市場（依通路）

  • 離線
  • 線上

12.美洲良性前列腺增生藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲良性前列腺增生藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太地區前列腺增生治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Alembic Pharmaceuticals Limited
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation
    • Cipla Ltd.
    • Coloplast Group
    • Dr. Reddy's Laboratories
    • Eli Lilly and Company
    • Endo International PLC
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals PLC
    • IPG Photonics Corporation
    • Lumenis Ltd.
    • Olympus Corporation
    • Organon group of companies
    • PROCEPT BioRobotics Corporation
    • ProstaLund AB
    • Quanta System
    • Richard Wolf GmbH
    • Teleflex Incorporated
    • Urologix, LLC.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 8.71 billion in 2024 and is projected to grow to USD 9.20 billion in 2025, with a CAGR of 5.91%, reaching USD 12.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 8.71 billion
Estimated Year [2025] USD 9.20 billion
Forecast Year [2030] USD 12.30 billion
CAGR (%) 5.91%

Exploring the Emerging Clinical Developments and Market Drivers Defining the Next Generation of Benign Prostatic Hyperplasia Treatment Paradigms

Benign prostatic hyperplasia (BPH) has emerged as a critical area of clinical focus due to its high prevalence among aging male populations and its profound impact on quality of life. As the demographic shift towards an older patient base accelerates, healthcare systems worldwide face mounting pressure to deliver safe, effective, and cost-efficient interventions. In recent years, the interplay of clinical innovation, patient preference, and evolving reimbursement pathways has partially redefined treatment objectives for moderate to severe lower urinary tract symptoms associated with prostatic enlargement.

The clinical pipeline now features an expanding array of pharmacotherapies aimed at both symptom relief and underlying disease modification. Novel agents targeting androgen pathways, inflammatory mediators, and smooth muscle tone within the prostate are under active investigation. Concurrently, minimally invasive technologies have transitioned from niche options to mainstream considerations, offering shorter recovery times and preserved sexual function relative to traditional surgical approaches. Moreover, professional guidelines have begun to integrate these advancements, urging a more personalized treatment algorithm based on symptom severity, prostate volume, and patient comorbidities.

Consequently, stakeholders across the public and private sectors are aligning around a paradigm that balances clinical efficacy with patient-centric factors such as procedure durability, side effect profiles, and access to care. This introduction sets the stage for an in-depth exploration of how recent clinical developments and market drivers converge to define the next generation of BPH treatment paradigms.

Identifying the Fundamental Technological and Regulatory Transformations Reshaping Treatment Modalities and Patient Outcomes in Prostatic Enlargement Management

The landscape of benign prostatic hyperplasia treatment is undergoing profound transformation driven by both technological breakthroughs and shifting regulatory frameworks. Historically dominated by heavy reliance on pharmacotherapy and transurethral resection surgery, the field now witnesses the rise of cutting-edge energy-based modalities, image-guided interventions, and targeted embolic therapies. These innovations aim to minimize procedural morbidity while preserving urinary and sexual function, key priorities for today's patient cohorts.

On the regulatory front, health authorities have begun to streamline pathways for minimally invasive medical devices and combination regimens, reflecting an increased willingness to consider surrogate endpoints and patient-reported outcomes. Harmonization efforts across major markets are reducing approval timelines for technologies that demonstrate safety and performance in robust clinical studies. Furthermore, the integration of real-world evidence into post-market surveillance has accelerated iterative improvements, enabling manufacturers to refine device designs and procedural techniques at an unprecedented pace.

As a result, treatment modalities once considered experimental are gaining momentum in routine practice. The convergence of technology, regulation, and patient-centered care is reshaping the fundamental approach to prostatic enlargement management. This section delves into these transformative forces, highlighting how they coalesce to create new opportunities for improved patient outcomes and streamlined clinical pathways.

Analyzing the Converging Effects of United States Tariff Adjustments on Treatment Access Supply Chains and Innovation Paths for Prostatic Hyperplasia Care

United States tariff adjustments announced in 2025 have generated ripple effects across global supply chains, impacting the cost structures and accessibility of key benign prostatic hyperplasia treatment components. Many medical devices-ranging from catheters and resectoscopes to urology lasers and implants-originate from or incorporate parts manufactured abroad. As import duties rise, distributors and healthcare providers confront increased procurement expenses, which in turn influence pricing negotiations and reimbursement discussions.

Manufacturers have responded by reassessing their production footprints, exploring near-sourcing strategies, and renegotiating supplier contracts to mitigate steep cost escalations. Simultaneously, emerging trade agreements and tariff exemptions for certain medical goods have provided limited relief, though administrative burdens remain substantial. Consequently, device innovators must balance the imperative to maintain margins with the need to ensure equitable patient access, particularly in outpatient and ambulatory surgical center settings.

Looking ahead, the tariff environment is likely to catalyze broader supply chain resilience measures within the industry. Strategic collaborations and investment in localized manufacturing are expected to gain prominence as companies seek to insulate their operations from future policy shifts. This analysis examines how recent tariff modifications are redefining procurement, distribution, and innovation pathways for prostatic hyperplasia care.

Uncovering Granular Treatment Type Product End User and Distribution Channel Segmentation Insights Shaping Approaches to Prostatic Hyperplasia Management

A nuanced understanding of market segmentation reveals critical inflection points for strategic investment and product development. When treatment type is considered, medications continue to hold foundational importance, with 5-alpha-reductase inhibitors and alpha blockers serving as first-line pharmacologic interventions. Yet the minimally invasive therapy segment, encompassing prostate artery embolization and water vapor therapy, is rapidly gaining traction due to shorter recovery times and favorable safety profiles. At the same time, surgical treatments have diversified beyond traditional transurethral resection of the prostate, now including laser surgery, prostatic urethral lift, and transurethral incision techniques that prioritize minimal tissue disruption.

Examining product type segmentation highlights the essential role of supporting technologies. Catheters, electrodes, and resectoscopes remain indispensable for interventional procedures, while prostatic stents and specialized urology lasers are becoming increasingly sophisticated in their design and application. Each category presents distinct development pathways, driven by evolving clinical requirements and user feedback from surgeons and interventional radiologists.

End-user analysis further clarifies market dynamics, as ambulatory surgical centers gain preference for office-based procedures while hospitals maintain their position in complex surgical cases. Clinics offering pharmacotherapy and minimally invasive office procedures are expanding service portfolios, and homecare models for medication management and post-procedure monitoring are on the rise. Finally, distribution channel trends underscore a transition from traditional hospital procurement networks toward integrated online platforms that streamline ordering, enable real-time inventory management, and support remote training modules for new devices.

Evaluating Geographic Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Inform Targeted Prostatic Hyperplasia Treatment Strategies

Regional dynamics play a pivotal role in shaping the benign prostatic hyperplasia treatment ecosystem, with each geography presenting unique regulatory, clinical, and economic considerations. In the Americas, robust reimbursement frameworks and early technology adoption drive rapid integration of both device-based therapies and advanced pharmacologics, supported by extensive clinical trial networks and established payer-provider collaborations.

In Europe, Middle East & Africa, diverse healthcare infrastructures foster a dual focus on cost containment and equitable access. Regulatory harmonization across the European Union facilitates cross-border device approvals, while emerging markets in the Middle East and Africa prioritize capacity building for minimally invasive techniques, often through international partnerships and training programs.

Across the Asia-Pacific region, accelerating population aging and growing awareness of male health issues are creating a surge in demand for both first-line medications and new procedural options. Governments are increasingly incentivizing local manufacturing and public-private research collaborations to expand access in less penetrated markets. Consequently, regional strategies must be tailored to navigate variations in clinical practice, reimbursement policies, and patient expectations across these diverse territories.

Highlighting Innovative Strategies Partnerships Competitive Dynamics Among Leading Biopharmaceutical Device Technology Companies in Prostatic Hyperplasia Care

Competitive dynamics in the benign prostatic hyperplasia arena are defined by a blend of established pharmaceutical firms and innovative device manufacturers. Leading drug makers leverage decades of portfolio experience in 5-alpha-reductase inhibitors and alpha blockers, while adjacent biopharma players explore novel combination therapies that address both symptom relief and tissue remodeling.

On the device side, global medical technology organizations continue to refine energy-based platforms, offering improved precision and reduced procedural times. Strategic partnerships between device innovators and contract research organizations have accelerated clinical validation, helping to secure favorable regulatory designations. At the same time, emerging companies specialize in niche delivery systems such as water vapor and embolic therapies, carving out competitive positions through targeted clinical data and differentiated user experiences.

The convergence of digital health and urology has also given rise to integrated software solutions that support pre-procedure planning, remote follow-up, and patient-reported outcome tracking. Consequently, the competitive field extends beyond core product offerings to encompass service ecosystems and data analytics capabilities that enhance long-term value for providers and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Clinical Effectiveness Market Penetration and Patient Adoption in Prostatic Hyperplasia Treatment

Forward-looking industry leaders should prioritize a multifaceted approach to maintain competitive advantage in the evolving benign prostatic hyperplasia market. First, investing in next-generation minimally invasive technologies-particularly those with outpatient or office-based application-will address patient demand for reduced recovery times and preserved quality of life. Establishing collaborative pilot programs with key opinion leaders and high-volume centers can accelerate adoption curves and generate compelling real-world evidence to support reimbursement negotiations.

Second, strengthening supply chain resilience through diversified sourcing and near-shoring initiatives will mitigate the financial impacts of evolving trade policies. Engaging in joint ventures with regional manufacturing partners can also facilitate market entry in underpenetrated territories. Third, integrating digital health tools into pre- and post-treatment pathways will enhance patient engagement and enable remote monitoring of outcomes, providing a richer data set for both clinical optimization and payer discussions.

Finally, customizing market access strategies to regional regulatory nuances-such as expedited device review programs in the Americas or harmonized EU approval processes-will streamline time to market. By synchronizing clinical development plans with local policy frameworks and reimbursement landscapes, companies can secure favorable positioning and drive sustainable growth across multiple geographies.

Detailing Rigorous Data Collection Analysis and Validation Protocols Ensuring Robustness of Research Findings in Prostatic Hyperplasia Market Assessment

This research employed a rigorous methodology combining comprehensive secondary research with targeted primary interviews and data triangulation. Initially, peer-reviewed journals, regulatory databases, patent filings, and industry white papers were systematically analyzed to construct a robust baseline of therapeutic modalities, device innovations, and policy developments. Historical regulatory approvals and guideline revisions were mapped to identify timing and scope of major market shifts.

Complementing the desk research, structured interviews with leading urologists, interventional radiologists, procurement specialists, and payers provided firsthand insights into clinical preferences, procedural workflows, and reimbursement challenges. Quantitative data points were validated through cross-referencing publicly available clinical trial registries and device approval summaries, ensuring consistency across multiple sources.

Finally, an iterative review process engaged subject matter experts to refine assumptions, resolve discrepancies, and contextualize findings within broader healthcare trends. This layered approach-incorporating secondary evidence, expert validation, and market feedback-underpins the reliability and depth of the strategic insights presented throughout this report.

Synthesizing Key Findings and Strategic Implications to Illuminate Future Directions and Opportunities in the Benign Prostatic Hyperplasia Treatment Arena

Bringing together the key findings reveals a market at the cusp of significant transition. Advances in minimally invasive therapies, alignment of regulatory pathways, and heightened tariff-driven supply chain considerations are collectively reshaping treatment algorithms and competitive dynamics. Segmentation analysis underscores the growing importance of non-surgical interventions and specialized product categories, while regional insights highlight the need for tailored market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

The interplay between established pharmaceutical agents and next-generation device platforms points to an integrated future in which combination therapies and digital health solutions drive patient-centered care. For stakeholders eager to navigate this complex ecosystem, the ability to anticipate policy shifts, forge strategic partnerships, and invest in differentiated technologies will determine long-term success. By synthesizing clinical innovation, operational resilience, and market intelligence, industry participants can capture emerging opportunities and deliver impactful outcomes for the growing BPH patient population.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increasing adoption of transurethral water vapor ablation driven by patient demand for minimally invasive care
  • 5.2. Growth in telehealth platforms enabling remote symptom monitoring and personalized BPH medication management
  • 5.3. Surge in development of selective five-alpha reductase inhibitors targeting improved side effect profiles
  • 5.4. Expansion of office-based prostatic urethral lift procedures reducing operational costs and improving recovery times
  • 5.5. Integration of artificial intelligence diagnostic tools for early detection and risk stratification of BPH progression
  • 5.6. Rising real-world evidence studies influencing value-based reimbursement for BPH therapies and interventions
  • 5.7. Emergence of combination therapies pairing beta-3 agonists with alpha-blockers to enhance urinary symptom relief
  • 5.8. Personalized dosing protocols informed by pharmacogenomic profiling to optimize treatment outcomes in BPH patients

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Medications
    • 8.2.1. 5-Alpha-Reductase Inhibitors
    • 8.2.2. Alpha Blockers
  • 8.3. Minimally Invasive Therapies
    • 8.3.1. Prostate Artery Embolization
    • 8.3.2. Water Vapour Therapy
  • 8.4. Surgical Treatments
    • 8.4.1. Laser Surgery
    • 8.4.2. Prostatic Urethral Lift
    • 8.4.3. Transurethral Incision Of The Prostate
    • 8.4.4. Transurethral Resection Of The Prostate

9. Benign Prostatic Hyperplasia Treatment Market, by Product Type

  • 9.1. Introduction
  • 9.2. Catheters
  • 9.3. Electrodes
  • 9.4. Implants
  • 9.5. Prostatic Stents
  • 9.6. Resectoscopes
  • 9.7. Urology Laser

10. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Clinics
  • 10.4. Homecare
  • 10.5. Hospitals

11. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
  • 11.3. Online

12. Americas Benign Prostatic Hyperplasia Treatment Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Alembic Pharmaceuticals Limited
    • 15.3.3. Asahi Kasei Corporation
    • 15.3.4. Astellas Pharma Inc.
    • 15.3.5. Bayer AG
    • 15.3.6. Boehringer Ingelheim GmbH
    • 15.3.7. Boston Scientific Corporation
    • 15.3.8. Cipla Ltd.
    • 15.3.9. Coloplast Group
    • 15.3.10. Dr. Reddy's Laboratories
    • 15.3.11. Eli Lilly and Company
    • 15.3.12. Endo International PLC
    • 15.3.13. GlaxoSmithKline plc
    • 15.3.14. Hikma Pharmaceuticals PLC
    • 15.3.15. IPG Photonics Corporation
    • 15.3.16. Lumenis Ltd.
    • 15.3.17. Olympus Corporation
    • 15.3.18. Organon group of companies
    • 15.3.19. PROCEPT BioRobotics Corporation
    • 15.3.20. ProstaLund AB
    • 15.3.21. Quanta System
    • 15.3.22. Richard Wolf GmbH
    • 15.3.23. Teleflex Incorporated
    • 15.3.24. Urologix, LLC.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHAI
  • FIGURE 24. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 25. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 26. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 191. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 192. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 205. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 206. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 219. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 233. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 234. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 243. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 276. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATME